基本信息
浏览量:795
职业迁徙
个人简介
Research Interests
Dr. Cleeland and his colleagues in the Department of Symptom Research have developed assessment tools (the Brief Pain Inventory, Brief Fatigue Inventory, and M. D. Anderson Symptom Inventory) to measure symptom severity and how symptoms interfere with patient functioning. These tools are widely used internationally in clinical trials evaluating symptom-management treatments. As Director of the WHO Collaborating Center for Supportive Cancer Care, Dr. Cleeland worked with colleagues in Asia, Europe, and the United States to verify that our symptom-assessment scales work well in various linguistic and cultural contexts to allow development of multinational clinical trials and cross-cultural epidemiological symptom studies. Through ongoing international collaborations, he works to further the stateside training of clinicians and researchers from other countries, provide resources to educate abroad, encourage treatment of cancer-related pain and other symptoms for those without access to expensive curative treatments, and promote palliative care programs in countries with limited health care resources. Dr. Cleeland's long-term research goals are to prevent the development of symptoms and to develop enhanced treatments for the symptoms of cancer and cancer treatment, which may lead to improvement in patient function, stress level, satisfaction with and willingness to endure therapy, and quality of life during and after treatment. He is especially interested in the role of inflammation as a physiological mechanism potentially responsible for symptom-cluster generation and in biological response modifiers as agents for symptom reduction and prevention. Based on animal models of inflammation-induced sickness behavior, he hypothesizes that inflammation and its downstream toxic effects represent a significant biological basis for subjectively reported clusters of symptoms, cognitive impairment, and neuropathies. Control or prevention of cancer-related cytokine dysregulation may provide a basis for experimental therapies that could significantly reduce or even preclude the emergence of cancer-related symptoms.
研究兴趣
论文共 893 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
FUTURE ONCOLOGYno. 10 (2024): 579-591
Charles S Cleeland,Karen N Keating,Brian Cuffel,Cem Elbi,Jonathan M Siegel, Christoph Gerlinger, Tara Symonds,Jeff A Sloan,Amylou C Dueck,Andrew Bottomley,Xin Shelley Wang,Loretta A Williams,
Scientific Reportsno. 1 (2024): 1-10
European Journal of Surgical Oncologyno. 7 (2024): 108396-108396
Journal of Clinical Oncologyno. 16_suppl (2024): 12084-12084
Annals of surgical oncologyno. 5 (2023): 2618-2619
Li Tang, Hongfan Yu, Wei Dai,Xiaojun Yang,Xing Wei, Xin Shelley Wang,Charles S. Cleeland,Qiang Li,Qiuling Shi
ANNALS OF SURGICAL ONCOLOGYno. 5 (2023): 2607-2617
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023): 12117-12117
The Lancet. Oncologyno. 2 (2023): E86-E95
Natalie Moryl,Tito R. Mendoza,Susan D. Horn, Jelyn C. Eustaquio,Charles S. Cleeland,Charles Inturrisi
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORKno. 11 (2023): 1132-+
加载更多
作者统计
#Papers: 880
#Citation: 73601
H-Index: 126
G-Index: 262
Sociability: 8
Diversity: 3
Activity: 42
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn